Modern Chinese Medicine Group Co. Ltd. AI Stock Analysis
Want to see HK:1643 full AI Analyst Report?
Modern Chinese Medicine Group Co. Ltd. (1643) AI Stock Analysis
Modern Chinese Medicine Group Co. Ltd.
(HKEX:1643)
The score is constrained primarily by deteriorating revenue and profitability, volatile and recently negative cash flow, and bearish technical positioning. The almost debt-free balance sheet provides meaningful resilience, but the negative P/E indicates that operational recovery is needed to improve the investment profile.
Modern Chinese Medicine Group Co. Ltd. (1643) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 298.80M
- Dividend Yield
- ―
- Average Volume (3M)
- 417.22K
- Price to Earnings (P/E)
- -5.4
- Beta (1Y)
- 0.60
- Revenue Growth
- 2.06%
- EPS Growth
- -298.25%
- Country
- Hong Kong
- Employees
- 189
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Modern Chinese Medicine Group Co. Ltd. Business Overview & Revenue Model
Company Description
As an investment holding company, Modern Chinese Medicine Group Co., Ltd. manufactures and distributes traditional Chinese pharmaceutical products, primarily targeting the middle-aged and elderly populations across the People's Republic of China. Its...
How the Company Makes Money
The company makes money mainly by selling traditional Chinese medicine products and related healthcare products through its distribution channels. Its revenue model is primarily product-driven: it generates revenue when it delivers finished TCM/propr...
Modern Chinese Medicine Group Co. Ltd. Financial Statement Overview
Summary
The nearly debt-free balance sheet is a significant strength, but sharply declining revenue, a move to losses, and recently negative free cash flow materially weaken overall financial performance.
Income Statement
30NegativeBalance Sheet
80PositiveCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 197.74M | 141.42M | 214.07M | 344.07M | 399.66M | 360.69M |
| Gross Profit | 27.30M | 22.73M | 55.20M | 104.17M | 170.79M | 158.43M |
| EBITDA | -12.59M | -4.63M | 33.10M | 74.75M | 130.03M | 117.02M |
| Net Income | -41.67M | -13.21M | 9.67M | 48.80M | 87.83M | 81.78M |
Balance Sheet | ||||||
| Total Assets | 499.10M | 543.63M | 540.31M | 528.53M | 501.53M | 395.94M |
| Cash, Cash Equivalents and Short-Term Investments | 119.66M | 229.81M | 229.67M | 286.27M | 282.26M | 176.09M |
| Total Debt | 1.20M | 69.03K | 135.00K | 72.00K | 393.00K | 410.00K |
| Total Liabilities | 30.79M | 45.43M | 56.08M | 55.64M | 78.60M | 58.58M |
| Stockholders Equity | 468.31M | 498.20M | 484.23M | 472.89M | 422.93M | 337.36M |
Cash Flow | ||||||
| Free Cash Flow | -126.10M | -16.58M | -55.32M | 3.38M | 114.06M | -12.87M |
| Operating Cash Flow | -105.08M | 4.85M | 58.98M | 8.48M | 125.79M | 57.60M |
| Investing Cash Flow | -84.87M | -35.37M | -115.49M | -4.19M | -11.05M | -70.05M |
| Financing Cash Flow | 26.28M | 28.68M | -144.00K | -326.00K | -8.73M | 115.76M |
Modern Chinese Medicine Group Co. Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1643, the sentiment is Negative. The current price of 0.39 is above the 20-day moving average (MA) of 0.36, below the 50-day MA of 0.58, and below the 200-day MA of 1.33, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 35.47 is Neutral, neither overbought nor oversold. The STOCH value of 24.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1643.
Modern Chinese Medicine Group Co. Ltd. Peers Comparison
Overall Rating
HK:023986Outperform
HK:095068Neutral
HK:166662Neutral
HK:089758.6Neutral- HK:164345Neutral
HK:149841Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0239 | 86Outperform | HKD 738.59M | 7.41 | 13.59% | 7.81% | 10.63% | 39.44% |
| HK:0950 | 68Neutral | HKD 641.83M | 3.71 | 8.02% | 5.50% | 7.05% | 22.46% |
| HK:1666 | 62Neutral | HKD 3.80B | 10.77 | 4.19% | 6.95% | -13.93% | -25.30% |
| HK:0897 | 59Neutral | HKD 412.32M | 97.22 | 0.34% | ― | -8.30% | -44.44% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1643 | 45Neutral | HKD 252.00M | -5.43 | -8.62% | ― | 2.06% | -298.25% |
| HK:1498 | 41Neutral | HKD 121.97M | -4.01 | -21.66% | ― | -6.71% | 43.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1643 | Modern Chinese Medicine Group Co. Ltd. | 0.39 | -0.33 | -46.53% | |
| HK:1666 | Tong Ren Tang Technologies Co Class H | 2.98 | -1.61 | -35.13% | |
| HK:0897 | Wai Yuen Tong Medicine Holdings Limited | 0.35 | -0.11 | -23.91% | |
| HK:0950 | Lee's Pharmaceutical Holdings Limited | 1.05 | -0.69 | -39.62% | |
| HK:1498 | PuraPharm Corp. Ltd. | 0.23 | -0.17 | -43.00% | |
| HK:0239 | Pak Fah Yeow International Limited | 2.37 | 0.11 | 5.05% |
Modern Chinese Medicine Group Co. Ltd. Corporate Events
Modern Chinese Medicine Group Ends VIE Structure After China Lifts TCM Manufacturing Curbs
Modern Chinese Medicine Group Co., Ltd. has announced the termination of its contractual arrangements structure used to control Chengde Yushi Jindan Pharmaceutical Co., Ltd. on the Chinese Mainland. This decision follows regulatory changes in the 202...
Modern Chinese Medicine Swings to Interim Loss Despite Surge in Revenue
Modern Chinese Medicine Group Co. Ltd. reported an 82.9% jump in revenue to RMB118.5 million for the six months ended 30 June 2026, with gross profit rising 36.4% to RMB22.1 million compared with a year earlier. Despite this top-line growth, the comp...
Modern Chinese Medicine Group Warns of Interim Loss Amid Expansion and R&D Push
Modern Chinese Medicine Group Co., Ltd. has issued a profit warning for the six months ended 30 June 2026, flagging an expected net loss of approximately RMB25.9 million versus a net profit of about RMB2.5 million a year earlier. The board attributes...
Modern Chinese Medicine Group Sets August Board Meeting for Interim Results and Dividend Review
Modern Chinese Medicine Group Co., Ltd. has scheduled a board meeting for 28 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The board will also consider proposing an interim dividend, a decision...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026